{
  "pmcid": "11302947",
  "sha256": "111cb4ce6024b2fc11221875f59ad1c1fbed838307ec00539d2a8052dc45a2e5",
  "timestamp_utc": "2025-11-09T15:17:32.004745+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.88880681818182,
    "reading_ease": 37.72096590909092,
    "word_count": 256
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants enrolled in TICH-2 were randomized to placebo or TXA."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants enrolled in TICH-2 were randomized to placebo or TXA."
      },
      "Objective": {
        "score": 1,
        "evidence": "We hypothesized that TXA would reduce the frequency of surgery (primary outcome) and improve functional outcome at 90 days in surgically treated patients in the TICH-2 data set."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "We hypothesized that TXA would reduce the frequency of surgery (primary outcome) and improve functional outcome at 90 days in surgically treated patients in the TICH-2 data set."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Participants enrolled in TICH-2 were randomized to placebo or TXA."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Neurosurgery was performed in 5.2% of participants (121/2325)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The number of patients receiving surgery who received TXA vs placebo were similar at 4.9% (57/1153) and 5.5% (64/1163), respectively"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The number of patients receiving surgery who received TXA vs placebo were similar at 4.9% (57/1153) and 5.5% (64/1163), respectively (odds ratio [OR] 0.893; 95% CI 0.619-1.289; P -value = .545)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}